Top Menu
  • Doctors
  • Locations
  • About
  • Financial Advocacy
  • Articles/News
  • Contact
  • Patient Portal
  • Make A Payment
Regional Cancer Care Associates
Call (844) 346-7222 Contact Us
Main Menu
  • Navigating Care
    • Getting Started
    • Oncology Medical Home
    • Cancer Types
    • Services
    • Clinical Trials
    • Side Effects Management
    • Cancer Care Support
    • Financial Advocacy
    • Patient & Caregiver Education
  • Cancer Types
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Fallopian Tube Cancer
    • Head & Neck Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Mesothelioma
    • Multiple Myeloma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Rectal Cancer
    • Skin Cancer
    • Stomach Cancer
    • Testicular Cancer
    • Thyroid Cancer
    • Uterine Cancer
  • Services
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
    • Hematology
    • Clinical Trials
    • Radiosurgery
    • Surgery
    • Genetic Testing
    • Palliative Care
    • Integrative Care
    • Pharmacy
    • Hospital Consultation
    • Blood & Marrow Stem Cell Transplantation
  • Clinical Trials
    • All Clinical Trials
  • For Providers
    • Care Coordination
    • Oncology Medical Home
    • Imaging Guidelines
rcca-header
Cancer Type: Multiple Myeloma

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

  • 1
  • 2
  • 3
  • 4
  • Next »

Find a Location

View All Locations


Find a Doctor

View All Doctors

Recent & Upcoming Events

  • “Look Good …Feel Better”
  • Watch Dr. Fang’s presentation “What’s New in Lung Cancer?”
  • Advances in Breast Cancer and New Developments

Recent News

  • African Americans And Cancer Risk – Test Your Knowledge: A Conversation with RCCA’s Dr. Seth Howard Berk March 28, 2018
  • Ovarian Cancer – What We Know Today About Risk Factors and Early Detection: A Conversation with RCCA’s Dr. Kenneth D. Nahum April 15, 2018
  • Testicular Cancer: Detection, Symptoms and Treatment March 21, 2018
Regional Cancer Care Associates
Corporate Office
25 Main Street, Suite 601
Hackensack, NJ 07601
Phone: (844) 346-7222
Fax: (201) 546-7892
info@regionalcancercare.org
  • About
  • Doctors
  • RCCA Management
  • RCCA Board
  • Locations
  • Events
  • Contact
  • For Providers
  • Careers
  • Notice of Privacy Practices
  • Privacy Policy

Find a Doctor

Find a Location

Facebook Twitter Youtube LinkedIn
© 2018 Regional Cancer Care Associates. All rights reserved. | Website by Healthcare Success.